Cargando…

Intronic SNPs of TP53 gene in chronic myeloid leukemia: Impact on drug response

BACKGROUND: TP53, located on chromosome 17p13, is one of the most mutated genes affecting many types of human cancers. Thus, we aimed at investigating the association of SNPs in TP53 gene with chronic myeloid leukemia (CML). MATERIALS AND METHODS: A total of 236 CML and 157 control samples were anal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sailaja, K., Rao, V. R., Yadav, Satish, Reddy, R. Rajasekhar, Surekha, D., Rao, D. Nageswara, Raghunadharao, D., Vishnupriya, S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3510914/ https://www.ncbi.nlm.nih.gov/pubmed/23225982 http://dx.doi.org/10.4103/0976-9668.101910

Ejemplares similares

Association of CYP3A5*3 polymorphism with development of acute leukemia
por: Rao, D. Nageswara, et al.
Publicado: (2011)

PvuII polymorphism of estrogen receptor-α gene in breast cancer
por: Surekha, D., et al.
Publicado: (2007)

Association of CYP19 polymorphisms with breast cancer risk: A case-control study
por: Surekha, Damineni, et al.
Publicado: (2014)

Influence of Caspase-9 polymorphisms on the development of Chronic Myeloid Leukemia- A case-control study
por: Edathara, Prajitha Mohandas, et al.
Publicado: (2018)

TP-0903 Is Active in Preclinical Models of Acute Myeloid Leukemia with TP53 Mutation/Deletion
por: Eisenmann, Eric D., et al.
Publicado: (2022)

TP53 intron 6 polymorphism and the risk of ovarian and breast cancer.
por: Mavridou, D., et al.
Publicado: (1998)

TP53-Mutated Myelodysplasia and Acute Myeloid Leukemia
por: Testa, Ugo, et al.
Publicado: (2023)

Functional Classification of TP53 Mutations in Acute Myeloid Leukemia
por: Dutta, Sayantanee, et al.
Publicado: (2020)

TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia
por: Rahmé, Ramy, et al.
Publicado: (2023)

Preexisting TP53 mutation in therapy-related acute myeloid leukemia
por: Schulz, Eduard, et al.
Publicado: (2014)

Clinical implications of subclonal TP53 mutations in acute myeloid leukemia
por: Prochazka, Katharina T., et al.
Publicado: (2019)

TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation
por: George, Binsah, et al.
Publicado: (2021)

Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations
por: Dutta, Sayantanee, et al.
Publicado: (2022)

TP53 Mutation in Acute Myeloid Leukemia: An Old Foe Revisited
por: Shin, Dong-Yeop
Publicado: (2023)

Intronic TP53 Polymorphisms Are Associated with Increased Δ133TP53 Transcript, Immune Infiltration and Cancer Risk
por: Eiholzer, Ramona A., et al.
Publicado: (2020)

Chronic myeloid leukemia: An Indian scenario
por: Digumarti, Raghunadharao
Publicado: (2016)

Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine
por: Bories, Pierre, et al.
Publicado: (2020)

TP53 Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge?
por: Molica, Matteo, et al.
Publicado: (2021)

TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome
por: Niparuck, Pimjai, et al.
Publicado: (2021)

Ascorbate Inhibits Proliferation and Promotes Myeloid Differentiation in TP53-Mutant Leukemia
por: Smith-Díaz, Carlos C., et al.
Publicado: (2021)

Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia
por: Cluzeau, Thomas, et al.
Publicado: (2021)

Targeting TP53-Mutated Acute Myeloid Leukemia: Research and Clinical Developments
por: Granowicz, Eric M, et al.
Publicado: (2022)

Are We Moving the Needle for Patients with TP53-Mutated Acute Myeloid Leukemia?
por: Shallis, Rory M., et al.
Publicado: (2022)

Rare Presentation of Acute Myeloid Leukemia With TP53 Mutation and Dermatologic Manifestations
por: Lott, Ronald, et al.
Publicado: (2023)

S127: DELTATP73 IMPOSES TP53 MUTANT-LIKE PHENOTYPES INCLUDING DRUG RESISTANCE AND POOR PROGNOSIS ON TP53-WILD TYPE ACUTE MYELOID LEUKEMIA.
por: Pereira-Martins, Diego A, et al.
Publicado: (2023)

Somatic intronic TP53 c.375+5G mutations are a recurrent but under‐recognized mode of TP53 inactivation
por: Chui, M Herman, et al.
Publicado: (2021)

TP53-mutant myelodysplastic syndrome and acute myeloid leukemia: the black hole of hematology
por: Patel, Shyam A., et al.
Publicado: (2022)

How I Treat TP53-Mutated Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Loschi, Michael, et al.
Publicado: (2022)

PB1820: CD47-BLOCKER TTI-622 COMBINED WITH AZACITIDINE IN PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA (AML) AND WITH AZACITIDINE + VENETOCLAX IN ELDERLY OR UNFIT PATIENTS WITH TP53-WILDTYPE AML
por: Daver, N., et al.
Publicado: (2022)

TP-0903 is active in models of drug-resistant acute myeloid leukemia
por: Jeon, Jae Yoon, et al.
Publicado: (2020)

VNTR Polymorphism in the Intron 5 of SIRT3 and Susceptibility to Breast Cancer
por: Payavula, Harshitha Yadav, et al.
Publicado: (2023)

Activating STING1-dependent immune signaling in TP53 mutant and wild-type acute myeloid leukemia
por: Kogan, Aksinija A., et al.
Publicado: (2022)

Identification and functional characterization of new missense SNPs in the coding region of the TP53 gene
por: Doffe, Flora, et al.
Publicado: (2020)

Therapeutic Targeting of TP53-mutated Acute Myeloid Leukemia by Inhibiting HIF-1α with Echinomycin
por: Wang, Yin, et al.
Publicado: (2020)

Kevetrin induces apoptosis in TP53 wild-type and mutant acute myeloid leukemia cells
por: Napolitano, Roberta, et al.
Publicado: (2020)

The Prognostic Value of TP53 Mutations in Adult Acute Myeloid Leukemia: A Meta-Analysis
por: Qin, Guoxiang, et al.
Publicado: (2022)

ASXL1, TP53 and IKZF3 mutations are present in the chronic phase and blast crisis of chronic myeloid leukemia
por: Menezes, J, et al.
Publicado: (2013)

Genomic landscape of TP53-mutated myeloid malignancies
por: Abel, Haley J., et al.
Publicado: (2023)

Genomic landscape of TP53-mutated myeloid malignancies
por: Abel, Haley J., et al.
Publicado: (2023)

Decitabine salvage for TP53-mutated, relapsed/refractory acute myeloid leukemia after cytotoxic induction therapy
por: Ferraro, Francesca, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vslkah0v34vlgus9rs1g09nca5